pd 98059 has been researched along with Disease Exacerbation in 22 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 7.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 3.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| "Human hepatocellular carcinoma (HCC) cell lines SMMC7721 and Huh7 were used." | 1.39 | Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. ( Ding, X; Dong, S; Gao, J; Ke, S; Kong, F; Kong, J; Sun, W; Wang, S; Zheng, L, 2013) |
| "Oral cancer is a prevalent type of cancer in Asian countries." | 1.35 | S-allylcysteine modulates the expression of E-cadherin and inhibits the malignant progression of human oral cancer. ( Chiang, EP; Chung, JG; Hsu, CY; Lee, HZ; Tang, FY, 2009) |
| "The role of the mTOR signal pathway in colorectal cancer (CRC) pathogenesis remains unclear, and the combination effect of PD98059 (an inhibitor for MEK) and rapamycin (an inhibitor for mTOR) on CRC is still unknown." | 1.35 | Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. ( Fang, JY; Sun, DF; Tian, XQ; Xiong, H; Zhang, YJ; Zhao, SL, 2009) |
| "Leptin is a hormone with multiple biological actions, produced predominantly by adipose tissue." | 1.32 | Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. ( Andó, S; Catalano, S; Giordano, C; Maggiolini, M; Marsico, S; Mauro, L; Montanaro, D; Panno, ML; Rago, V; Rizza, P, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (68.18) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, G | 1 |
| Cheng, Y | 1 |
| Zhang, Q | 1 |
| Li, X | 1 |
| Zhou, J | 1 |
| Wang, J | 1 |
| Wei, L | 1 |
| Borges, CS | 1 |
| Ferreira, AF | 1 |
| Almeida, VH | 1 |
| Gomes, FG | 1 |
| Berzoti-Coelho, MG | 1 |
| Cacemiro, MDC | 1 |
| Nunes, NS | 1 |
| Figueiredo-Pontes, LL | 1 |
| Simões, BP | 1 |
| Castro, FA | 1 |
| Monteiro, RQ | 1 |
| Dong, S | 1 |
| Kong, J | 2 |
| Kong, F | 1 |
| Gao, J | 1 |
| Ke, S | 1 |
| Wang, S | 1 |
| Ding, X | 1 |
| Sun, W | 1 |
| Zheng, L | 1 |
| Martín, P | 1 |
| Mora, I | 1 |
| Cortes, MA | 1 |
| Calleros, L | 1 |
| García-Jerez, A | 1 |
| Ortiz, A | 1 |
| Rodríguez-Puyol, M | 1 |
| Rodríguez-Puyol, D | 1 |
| Olmos, G | 1 |
| Tokay, E | 1 |
| Kockar, F | 1 |
| Davis, JE | 1 |
| Xie, X | 1 |
| Guo, J | 1 |
| Huang, W | 1 |
| Chu, WM | 1 |
| Huang, S | 1 |
| Teng, Y | 1 |
| Wu, G | 1 |
| Slipicevic, A | 2 |
| Jørgensen, K | 2 |
| Skrede, M | 2 |
| Rosnes, AK | 1 |
| Trøen, G | 1 |
| Davidson, B | 1 |
| Flørenes, VA | 2 |
| Tang, FY | 1 |
| Chiang, EP | 1 |
| Chung, JG | 1 |
| Lee, HZ | 1 |
| Hsu, CY | 1 |
| Zhang, YJ | 1 |
| Tian, XQ | 1 |
| Sun, DF | 1 |
| Zhao, SL | 1 |
| Xiong, H | 1 |
| Fang, JY | 1 |
| Matsumoto, T | 1 |
| Ishida, K | 1 |
| Nakayama, N | 1 |
| Kobayashi, T | 1 |
| Kamata, K | 1 |
| Ishii, N | 1 |
| Matsumura, T | 1 |
| Kinoshita, H | 1 |
| Fukuda, K | 1 |
| Motoshima, H | 1 |
| Senokuchi, T | 1 |
| Nakao, S | 2 |
| Tsutsumi, A | 1 |
| Kim-Mitsuyama, S | 1 |
| Kawada, T | 1 |
| Takeya, M | 1 |
| Miyamura, N | 1 |
| Nishikawa, T | 1 |
| Araki, E | 1 |
| Lin, SY | 1 |
| Liang, YC | 1 |
| Ho, YS | 1 |
| Tsai, SH | 1 |
| Pan, S | 1 |
| Lee, WS | 1 |
| Nakata, H | 2 |
| Uemura, Y | 2 |
| Kobayashi, M | 2 |
| Harada, R | 1 |
| Taguchi, H | 2 |
| Harja, E | 1 |
| Bucciarelli, LG | 1 |
| Lu, Y | 1 |
| Stern, DM | 1 |
| Zou, YS | 1 |
| Schmidt, AM | 1 |
| Yan, SF | 1 |
| Catalano, S | 1 |
| Mauro, L | 1 |
| Marsico, S | 1 |
| Giordano, C | 1 |
| Rizza, P | 1 |
| Rago, V | 1 |
| Montanaro, D | 1 |
| Maggiolini, M | 1 |
| Panno, ML | 1 |
| Andó, S | 1 |
| Yoo, YG | 1 |
| Yeo, MG | 1 |
| Kim, DK | 1 |
| Park, H | 1 |
| Lee, MO | 1 |
| Xu, L | 1 |
| Deng, X | 1 |
| Cruciani, V | 1 |
| Mikalsen, SO | 1 |
| Kubota, T | 1 |
| Bandobashi, K | 1 |
| Saito, T | 1 |
| Cavarretta, IT | 1 |
| Neuwirt, H | 1 |
| Untergasser, G | 1 |
| Moser, PL | 1 |
| Zaki, MH | 1 |
| Steiner, H | 1 |
| Rumpold, H | 1 |
| Fuchs, D | 1 |
| Hobisch, A | 1 |
| Nemeth, JA | 1 |
| Culig, Z | 1 |
| Inagaki, Y | 1 |
| Higashi, K | 1 |
| Kushida, M | 1 |
| Hong, YY | 1 |
| Higashiyama, R | 1 |
| Moro, T | 1 |
| Itoh, J | 1 |
| Mikami, T | 1 |
| Kimura, T | 1 |
| Shiota, G | 1 |
| Kuwabara, I | 1 |
| Okazaki, I | 1 |
| Koschmieder, S | 1 |
| Hofmann, WK | 1 |
| Kunert, J | 1 |
| Wagner, S | 1 |
| Ballas, K | 1 |
| Seipelt, G | 1 |
| Hoelzer, D | 1 |
| Ottmann, OG | 1 |
| Kalina, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Serum Autotaxin as a Potential Biomarker in Systemic Lupus Erythematosus Patients and Its Relation to Disease Activity.[NCT06063668] | 94 participants (Anticipated) | Observational | 2023-10-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 other studies available for pd 98059 and Disease Exacerbation
| Article | Year |
|---|---|
ATX‑LPA axis facilitates estrogen‑induced endometrial cancer cell proliferation via MAPK/ERK signaling pathway.
Topics: Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Endometrial Neo | 2018 |
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Chromones; Di | 2018 |
Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Chromones; Disease Progress | 2013 |
Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis.
Topics: Acute Kidney Injury; Animals; Apoptosis; Cells, Cultured; Cyclic GMP-Dependent Protein Kinase Type I | 2014 |
Identification of intracellular pathways through which TGF-β1 upregulates URG-4/URGCP gene expression in hepatoma cells.
Topics: Androstadienes; Cell Line, Tumor; Cell Proliferation; Disease Progression; Enzyme Inhibitors; Flavon | 2016 |
ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling.
Topics: ADP-Ribosylation Factor 1; Animals; Butadienes; Carcinogenesis; Cell Line, Tumor; Cell Proliferation | 2016 |
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells.
Topics: Biomarkers, Tumor; Carcinogens; Carrier Proteins; Cell Nucleus; Cell Proliferation; Cytoplasm; Disea | 2008 |
S-allylcysteine modulates the expression of E-cadherin and inhibits the malignant progression of human oral cancer.
Topics: Adherens Junctions; Cadherins; Cell Proliferation; Cysteine; Disease Progression; Enzyme Activation; | 2009 |
Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Disease | 2009 |
Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat.
Topics: Angiotensin II; Animals; Arginine Vasopressin; Butadienes; Diabetes Mellitus, Type 2; Diabetic Angio | 2009 |
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
Topics: Amlodipine; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Bin | 2010 |
Involvement of both extracellular signal-regulated kinase and c-jun N-terminal kinase pathways in the 12-O-tetradecanoylphorbol-13-acetate-induced upregulation of p21(Cip1) in colon cancer cells.
Topics: Adenocarcinoma; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Chromosome Mapping; Colonic Neoplasms | 2002 |
Cyclooxygenase-2 inhibitor NS-398 suppresses cell growth and constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells.
Topics: Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoproston | 2003 |
Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation.
Topics: Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Blood Glucose; Calcium-Calmodulin-Dependent Pro | 2004 |
Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells.
Topics: Adipose Tissue; Cell Line, Tumor; Cell Nucleus; Disease Progression; Down-Regulation; Enzyme Inhibit | 2004 |
Novel function of orphan nuclear receptor Nur77 in stabilizing hypoxia-inducible factor-1alpha.
Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Nucleus; Disease Progression; DNA-Bind | 2004 |
Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion.
Topics: Blotting, Western; Calpain; Carcinogens; Cell Line, Tumor; Cell Movement; Disease Progression; Dose- | 2004 |
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2.
Topics: Anoikis; Apoptosis; Butadienes; Carbazoles; Cell Adhesion; Cell Culture Techniques; Cell Cycle; Cell | 2005 |
Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways.
Topics: Adenocarcinoma; Cell Death; Cell Line, Tumor; Chromones; Disease Progression; Enzyme Activation; Ext | 2006 |
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1.
Topics: Antibodies, Monoclonal; Apoptosis; Autocrine Communication; Disease Progression; Flavonoids; Gene Ex | 2007 |
Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7.
Topics: Animals; Antibodies; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Cells, Culture | 2008 |
TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS.
Topics: Acute Disease; Adult; Antigens, CD34; Cell Division; Disease Progression; DNA Replication; DNA-Bindi | 2001 |